Drug intelligence / Profile preview

OTOV101

Development stage: Preclinical
Lead developer: Otovia Therapeutics
Modality: Gene Therapies
Administration: Otic

Overview

**OTOV101** is an investigational dual-adeno-associated virus gene-replacement therapy developed for autosomal recessive deafness 9 caused by pathogenic **OTOF** variants. The product comprises the paired AAV vectors OTOV101N and OTOV101C, which deliver complementary portions of the human *OTOF* coding sequence to cochlear inner hair cells. Intracellular reconstruction and expression of full-length otoferlin is intended to restore synaptic vesicle exocytosis at inner-hair-cell auditory synapses and thereby improve hearing. OTOV101 has been evaluated in an investigator-initiated clinical study using intracochlear administration for DFNB9 deafness.

Brand names: OTVO101N + OTOV101C
Other names: AAV-OTOFOTOV 101OTOV101OTOV-101OTOV101N + OTOV101C

Targets

OTOF (Otoferlin)

Beyond the preview

Go deeper on OTOV101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTOV101.

Explore the full profile